• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
```
Home»Posts tagged with»Vivacity-MG3

Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?

By Pallavi Madhiraju on June 30, 2026   Pharma & Biotech  

Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?

Discover what Johnson & Johnson’s new IMAAVY data mean for earlier gMG treatment, sustained control, safety and FcRn competition.

Recent Posts

  • Enhertu wins EU tumor-agnostic approval, but HER2 testing will decide its real impact
  • Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes?
  • Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial
  • FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose
  • Sobi’s NASP FDA setback turns uncontrolled gout opportunity into a manufacturing test
  • Can IMAAVY’s sustained control data reshape earlier treatment of generalized myasthenia gravis?
  • Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
  • Nippon Shinyaku backs EXG-7001 as full-length dystrophin mRNA strategy enters Duchenne race
  • Can Anixa’s breast cancer vaccine and lira-cel CAR-T therapy translate early immune signals into clinical benefit?
  • Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi
  • Why LEO Pharma is shifting the chronic hand eczema debate from skin clearance to life impact
  • Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes